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1Introduction
At its twentieth special session devoted to countering the world drug
problem together, in 1998, the General Assembly of the United
Nations adopted a Political Declaration (resolution S-20/2, annex), by
which it decided to establish the year 2008 as a target date for States,
with a view to eliminating or reducing significantly the illicit manu-
facture, marketing and trafficking of psychotropic substances, includ-
ing synthetic drugs, and the diversion of precursors. That was the first
time that the international community had agreed on such specific
drug control objectives. Monitoring and evaluating progress towards
those goals requires systematic data and, for that reason, at that spe-
cial session, the General Assembly requested the United Nations
Office on Drugs and Crime [1] to provide States Members of the
United Nations with the assistance necessary for compiling compara-
ble data on drug use, to collect and analyse those data and to report
thereon to the United Nations Commission on Narcotic Drugs. In
response to those requests, the Office launched the Global Assessment
Programme on Drug Abuse (GAP), the aims of which are:
(a) To support Member States in building the systems neces-
sary for collecting reliable data to inform policy and action;
(b) To encourage regional partnerships for the sharing of expe-
riences and technical developments; and
(c) To facilitate a better understanding of global patterns and
trends in drug abuse by encouraging the adoption of sound
methods of collecting comparable data at country, regional
and global levels.
Those aims reflect the challenge posed in the Declaration on the
Guiding Principles of Drug Demand Reduction adopted by the General
Assembly at its twentieth special session (resolution S-20/3, annex),
which calls for regular assessments of the nature and magnitude of
drug abuse and drug-related problems in the population as the basis
for demand reduction programmes. Those assessments should be
undertaken in a comprehensive, systematic and periodic manner,
drawing on results of relevant studies, allowing for geographical con-
siderations and using similar definitions, indicators and procedures to
assess the drug situation.
Part II of the Annual Reports Questionnaire (ARQ) provides Member States with a
mechanism for reporting data on drug abuse under the international drug control
treaties [2]. In establishing the technical networks necessary to collate ARQ data,
Governments are also investing in information networks that can pay valuable divi-
dends at the national level. It should be noted that the factor that most inhibits
the development of a comprehensive picture of patterns and trends in illicit drug
abuse remains the limited capacity available in many countries to collect informa-
tion in that area. The ARQ has an important role to play in encouraging countries
to develop data collection systems and facilitating capacity-building exercises in
Member States, supported by the Office on Drugs and Crime through GAP activi-
ties. A technically sound questionnaire is only one of the requirements in success-
fully compiling a comprehensive global data set on patterns and trends in drug
abuse. Equally important is ensuring that the process by which data are compiled
and submitted is efficiently managed.
The present publication, Annual Reports Questionnaire, Part II: Extent, Patterns
and Trends of Drug Abuse: Guide to Completion, was prepared under the Global
Assessment Programme on Drug Abuse as part of GAP Toolkit Module 4:
Management of Data for the Annual Reports Questionnaire, which also comprises
a set of four interlinked training packs designed to assist Member States in com-
pleting and interpreting part II of the questionnaire for purposes of policy forma-
tion and implementation of demand reduction activities. Training pack 1, Annual
Reports Questionnaire, Part II: Content and Conceptual Issues, presents the topics
covered by part II of the questionnaire, terminology and conceptual issues. Training
pack 2, Monitoring Drug Abuse for Policy and Practice, discusses the relationship
among monitoring, policy and practice and the development of a national drug
information system. Training pack 3, Completing the Annual Reports Questionnaire,
Part II: Practical Issues and Detailed Guidance Notes, contains practical instruc-
tions on organizing completion of and submitting part II of the questionnaire.
Training pack 4, Annual Reports Questionnaire, Part II: Terminology, provides key-
word definitions of some basic drug epidemiological terms used in the question-
naire. The present Guide to Completion of Part II is primarily aimed at persons
responsible for national drug abuse data and technical persons responsible for com-
pletion of part II of the ARQ. GAP Toolkit Module 4 provides more in-depth infor-
mation on the issues covered by part II of the questionnaire, which may be useful
to those compiling and recording data, as well as to a wider readership, including
trainers.
Module 4: Management of Data for the Annual Reports Questionnaire forms one 
component of the GAP Toolkit, a compendium of methodological guides on drug
abuse epidemiology, produced to assist States Members of the United Nations in
developing systems of drug information collection that are culturally appropriate and 
relevant, in bringing existing drug information systems into conformity with inter-
nationally recognized standards of good practice and in harmonizing drug abuse indi-
cators. The other modules in the Toolkit series provide support in the following
areas: developing an integrated drug information system, estimating prevalence, con-
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ducting school surveys on drug abuse, basic data analysis, qualitative research and
focused assessments, and ethical guidelines in drug abuse epidemiology [3]. 
Other activities of the Global Assessment Programme on Drug Abuse include the
provision of technical and financial support for the establishment of drug informa-
tion systems and support for and coordination of global data collection activities.
Further information about GAP may be obtained from the GAP web site at
www.unodc.org/unodc/en/drug_demand_gap.html, from the Global Challenges
Section at the United Nations Office on Drugs and Crime, PO Box 500, 1400 Vienna,
Austria, or by sending an e-mail to the following address: gap@unodc.org.
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The annual reports questionnaire, part II, has 10 sections, covering
the following topics:
(a) Prevalence of drug abuse among the general population, pages
4-7, questions Q1-Q9;
(b)
pages 8 and 9, questions Q10-Q14;
(c) Injecting drug abuse, pages 10 and 11, questions Q15-Q22;
(d) Severe drug abuse, page 12, questions Q23-Q28;
(e) New developments in prevalence and patterns of drug abuse,
pages 13 and 14, questions Q29-Q32;
(f) Drug-related morbidity, page 15, questions Q33-Q38;
(g) Drug-related mortality, pages 16 and 17, questions Q39-Q47;
(h) Drug treatment, pages 18 and 19, questions Q48-Q58;
(i) Data collection capacity, page 20, questions Q59-Q61;
(j) Reports and additional information, pages 21-23.
Information is requested in column headings, while the response for-
mat has generally been given a tabular design to accommodate the
need to report on topics for individual classes or types of drug. Two
distinct levels of information are requested: “summary expert opin-
ions” and “quantitative estimates”. This distinction recognizes the fact
that, as yet, many countries do not have detailed quantitative data
on the topics concerned. To accentuate the distinction, the questions
relating to summary expert opinions and those relating to quantita-
tive estimates have been given different background colours. 
Specification of class or type of drug
Although the questionnaire, part II, covers all substances controlled
by the United Nations conventions on narcotic drugs and psychotropic
substances, the health and social impact and consequences of indi-
vidual drugs vary considerably and any assessment of the extent, pat-
terns and trends of drug abuse that lumped together all illicit drugs
would not be informative. Most questions in the ARQ therefore relate
Prevalence of drug abuse among the school (youth) population,
Chapter I
to individual classes or types of drug and should preferably be answered in terms
of individual drugs.
The classes and types of drug that are globally considered relevant for each topic
are already listed in the ARQ, but if the pre-coded lists do not include drugs preva-
lent in the country being reported on, other drugs or aggregate groups of drugs may
be added in the appropriate text fields. An overview of the classification of classes
and types of drug can be found in chapter VI below; for more detailed information
on the classification of drugs, the publication Terminology and Information on Drugs
[4]  should be consulted. 
Summary expert opinions
The questionnaire asks for summary expert opinions to be provided on topics cov-
ered in three types of question:
(a) The occurrence of individual classes or types of drug. Are specific drugs known
to have been used in the country (Q1), to have been injected (Q15), to have
been involved in drug-related deaths (Q39) or to have been the primary cause
for drug treatment (Q48)? In a similar way, question Q33 asks if infections
with hepatitis B or C or HIV have occurred among drug injectors. The answer
categories for these questions are simply “yes” or “no";
(b) The relative magnitude of use of individual drugs among other drugs that have
been used (Q2), involved in drug-related deaths (Q40) or been the primary
cause of drug treatment (Q49). These questions should be answered by indi-
cating an order of ranking of classes or types of drug;
(c) The trend for specific drugs with regard to use (Q4), injecting use (Q16), drug-
related deaths (Q41) and drug treatment (Q50). The answer categories for
these questions constitute a five-point scale ranging from “large increase” to
“large decrease”.
All questions refer to the past year, that being the reporting period. Although the
questions listed above can sometimes be answered on the basis of sound scientific
evidence, in the ARQ they are primarily intended to represent general “qualitative”
information. If there are no data based on surveys, registers or formal estimation
methods, the questions may be answered on the basis of the opinions of informed
experts only and it is assumed that all countries can provide information at least
at this qualitative level.
Summary expert opinions, however, are not simply introduced into the ARQ to com-
pensate for missing quantitative data. The types of question that are labelled sum-
mary expert opinions deal with different issues that often cannot be answered
intelligibly by only considering quantitative data. In practice, the expert opinions
will be based on various sources of information, ranging from hard evidence of quan-
titative data and scientific analysis to results of qualitative studies and general pro-
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fessional experience, but they will also take the context of the information into
account. The requested qualitative expert opinions are intended to supplement rather
than replace quantitative data.
Thus, the occurrence of particular drugs in the country might be known by experts in
the field long before they were revealed by quantitative treatment data or survey results.
An order of ranking of the drugs being used may be deduced from quantitative esti-
mates, but estimation methods for individual drugs are not always specific and preva-
lence figures based on survey data may not differentiate between incidental and regular
use, whereas such a distinction could be made by experts in the country in order to
decide on the relative magnitude of drug abuse. For example, if there are more inci-
dental users of Ecstasy than regular users of cocaine, experts in the country might
still rank cocaine above Ecstasy, taking into account the general pattern of use.
Trends can, of course, be assessed by comparing time series of quantitative data.
This will reveal if drug use has risen or dropped, but it will not answer the ques-
tion of how such a change could be labelled in the context of the country being
reported on. A 10 per cent increase in, for example, cannabis (that is, the number
of people who have used cannabis in the past year has increased by 10 per cent
compared to the previous year) might be considered a large increase if there had
previously been a high number of users, but could be regarded as “no great change”
if the number of users had previously been very low. The reporting of trends in
terms of large or small changes is not only based on objective quantitative figures,
but also depends on the context and the perception of changes in the country.
Presenting expert opinions in the ARQ implies that these opinions have been
assessed prior to completion of the ARQ. Although there is no standard methodol-
ogy for this assessment, the following basic methods could be applied:
(a) Asking various experts in the country to complete the relevant sections of the
ARQ. The average result, possibly after weighting the responses of individual
experts on the basis of their assumed expertise and experience, could then be
entered as the country’s response to the expert opinion questions in the ARQ;
(b) Asking various experts in the country to complete the relevant sections of the
ARQ and then presenting them with the collective results, with the request to
review their initial responses while taking into account the responses of others.
This cyclic method of expert consultation, known as the Delphi-approach,
involves an implicit weighting of individual responses by each of the experts
and usually results in a consensus view being reached on the issues concerned;
(c) Organizing a consensus-seeking meeting, during which different experts would
try to decide on a collective response to the expert opinion questions in the
ARQ. In such a meeting, the opinions of individual experts would not only be
shaped by the views of others, but also by their arguments and normally the
meeting would result in an accepted consensus on the country’s reply to the
expert opinion questions of the ARQ.
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Any consultation of experts requires the careful selection of people who have the
necessary expertise and experience. If the model procedure for completion of the
ARQ described in chapter II is followed, the identification of relevant experts is the
first step in the process. The selection principle should be that an attempt is made
to assemble the best expertise in the country. Experts chosen initially may assist in
the selection of others, but the selection should not be based on a random sample
from nominated experts. 
Quantitative estimates
For each topic, the questionnaire asks if there are quantitative estimates or statis-
tics available. The indicator tables on drug prevalence (questions Q8 and Q9 and
Q12-Q14) also allow alternatives to be specified for the preferred prevalence meas-
ure and age groups.
Estimates should be provided for the reporting year. Where this is not possible, the
most recent figures available may be included. The year of the estimate should always
be specified. References to the sources of the estimates may be included in the sec-
tion entitled “Reports", which follows question Q60.
Estimates relating to different drugs do not have to be taken from the same sources.
For example, an estimate of the prevalence of cannabis use may be based on the
results of a general population survey, whereas an estimate of the prevalence of 
heroin use may be based on a capture-recapture method involving treatment data.
However, it should be ensured that the estimated figures reported are estimates for
the country as a whole and apply to the same year.
If no estimate is available for the country as a whole, an estimate for a part of the
country or for a sub-population may be specified. In the ARQ this is called a “par-
tial estimate”. If more than one such partial estimate is available, the one that is
considered to be a reasonable alternative to a recent national estimate may be cho-
sen. For partial estimates, not only the year of the estimate should be specified, but
also the geographical or population coverage, as well as the size of the reference
population to which the estimate applies.
National and partial estimates or partial estimates referring to different sub-
populations or parts of the country should not be mixed within the same table of
indicator data. For example, if there is a national estimate for heroin and only a par-
tial estimate for amphetamine, only the national estimate for heroin should be entered
in the table. The partial estimate for amphetamine may be specified in the section
entitled “Additional information”, which appears at the end of the questionnaire.
Similarly, if only partial estimates are available, but with different coverage for indi-
vidual drugs, only the figures for drugs that have the same year and coverage of the
estimate should be entered. Figures for drugs that cover a different sub-population or
refer to a different year may be provided, together with details of the year, coverage
and size of the reference population, in the section for additional Information. 
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In many cases, a variety of quantitative and qualitative data relating to certain areas
or sub-populations may be available, none of which by themselves might be con-
sidered a reasonable alternative for a national estimate. In such cases, it may be bet-
ter to generate a national estimate for the ARQ on the basis of an inductive process
by the country’s experts. This means that the experts start from general notions
about the real situation in the country and try to find arguments based on the frag-
mented data available to confirm or contradict these initial notions in order to decide
on a qualitative estimate for the country as a whole. If such a method is used in
the process of completion of the ARQ, the estimation process and the arguments
involved should be documented. The reference year of the estimate will then be the
reporting year of the ARQ and details of the inductive process employed should be
given in the section for “Reports” on page 21 of the questionnaire. 
Reports and additional information
In the section entitled “Reports” on page 21 of the questionnaire, references to rel-
evant national reports or major studies on the extent and patterns of or trends in
drug abuse in the country may be listed. At a minimum, references should be pro-
vided to the publications containing details of the quantitative estimates supplied
in the preceding sections of the ARQ. If possible, electronic or hard copies of the
reports listed in the completed questionnaire should be attached, in particular when
such reports have not been published. If a report is available on the Internet, the
URL address should be supplied.
The section entitled “Additional information” on pages 22 and 23 should be used
first to specify answers to previous questions that exceeded the size of the corre-
sponding form fields (see questions Q7, Q11, Q20, Q26, Q28, Q30, Q32, Q36, Q43,
Q52 and Q61) and to provide information not consistent with the figures reported
in the indicator tables. The section may also be used to add any information on the
drug situation of the country in the previous year that was not covered in the ARQ. 
It should be noted that the section entitled “New developments in prevalence and
patterns of drug abuse” includes a text field on page 14 for the documenting of
developments in prevalence and patterns of drug abuse other than those covered by
earlier questions and this field should be used before the section entitled “Additional
information” for the reporting of supplementary information.

Preparation for completion of
the questionnaire 
Chapter II
11
The ARQ asks for information that no one expects the responding
government officials to have ready to hand. Completion of the ARQ
requires careful preparation. Even if the country has a dedicated sur-
veillance system on drug abuse, the requested information will still
need to be collected and extracted from various reports, documents
or computer databases.
In many cases, the information available cannot simply be copied into
the ARQ because it is based on different definitions and categories,
because it does not describe the situation in the country as a whole
and covers only certain cities or regions, or because it does not relate
to the reporting year of the ARQ. In such cases, additional actions
are needed to obtain national estimates for the reporting year from
such incomplete, fragmented or outdated sources. 
In many cases too, information on topics covered by the ARQ is not
available in existing documents or databases because it has not yet
been reported or because an appropriate infrastructure to collect such
information is not yet in place. The United Nations Office on Drugs
and Crime works to improve the capacities of countries for data col-
lection and reporting with regard to drug abuse [5], but, even if such
operational monitoring systems have yet to be established, at least a
part of the ARQ should be completed. In the absence of written
reports and computerized databases, experts in the country with pro-
fessional knowledge and expertise on the topics of the ARQ may be
consulted to obtain the basic information needed to complete the
ARQ for the country. Moreover, such experts may also be able to
assist in collecting, sorting and interpreting any existing information
available for the purpose of completing the ARQ.
For successful completion of the ARQ, it is recommended that offi-
cials completing the questionnaire: 
(a) Familiarize themselves with the content and structure of the
ARQ;
(b) Identify which persons or institutions hold information and/or
expertise on the various topics of the ARQ. If the country has a national drug
agency or narcotics board it or they should be involved, but other expertise
in the country should also be sought, in particular when such central gov-
ernment bodies are predominantly oriented towards law enforcement; 
(c) Establish a working committee to prepare the country’s response to the ARQ.
The members should be key experts identified in (b) above. For some coun-
tries, it might be more convenient to select an appropriate institution to pre-
pare answers for the ARQ on behalf of the Government;
(d) Collect reports, papers and database descriptions that may contain informa-
tion relevant for answering the questions raised in the ARQ; 
(e) Extract from the collected documentation or from the identified databases all
information relevant to the topics of the ARQ; 
(f) Select the information that matches the demands of the ARQ, that is, infor-
mation based on the same definitions, presented in the same report formats,
covering the national situation and relating to the ARQ reporting year. This
selected information can be entered into a draft version of the completed ARQ;
(g) Select also information that does not fully match ARQ definitions, report for-
mats or coverage, but nevertheless deals with the same issues as the ques-
tions of the ARQ. Discuss with the chosen experts to what extent that
information could be used to complete the ARQ, if necessary applying addi-
tional data manipulations, estimation techniques or other commonly accepted
adjustments and interpretations;
(h) Perform the necessary adaptations on the information gathered in procedure
(g) above to make it ready for entering in the draft version of the completed
ARQ; 
(i) Discuss with the chosen experts to what extent the remaining questions of
the ARQ, for which no answers could be generated after the procedures
described in (f) and (h) above, could be answered on the basis of common
expertise or experience. If such answers are possible, they may also be entered
in the draft version of the completed ARQ;
(j) Check the draft version of the completed ARQ for consistency and add, if
applicable, supporting documentation, then finalize the completion of the
ARQ.
Developing a system for completion of the ARQ and involving key experts of the
country not only facilitates the effort, but also enhances the quality of the country’s
response. Moreover, implementation of a systematic procedure with repeated expert
consultation is a precondition for the development and maintenance of a sustain-
able monitoring system to support evidence-based policy and practice in the future.
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completion
Chapter III
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The present ARQ form is designed for electronic completion using a
computer, but it may also be completed manually in handwriting or
by typewriter. In either case, completion involves adding text, num-
bers or ticks in the form fields that correspond to the questions (see
figure I).
Boxes and form fields should be left blank if the answer is not known
or the required figure cannot be provided. Fields left empty will be
interpreted as “no information available”. However, when figures are
equal to the value zero, 0 or 0.0 should be entered in form fields
rather than leaving them blank, otherwise the answer will be inter-
preted as missing.
14
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Manual completion
Text, numbers or ticks should be entered in the white spaces of the form fields. If
the ARQ is completed manually, block capitals should be used. If a typewriter is used,
the individual pages of the document should be detached and filled in one by one.
Often, completion requires only marking the boxes corresponding to the answer. In
such cases, the appropriate square box may be marked with a solid point, a cross
or a tick. If a typewriter is used, it might still be easier and faster to mark the boxes
manually rather than try to align the form fields in the typewriter
Electronic completion
For electronic completion, either the Acrobat form (file extension .pdf) or the Word
form (file extension .doc) may be used. Both formats allow movement from one form
field to another by using the cursor or by using the TAB key, but it is generally 
easier to use the cursor, as this allows direct movement to any field, whereas using
the TAB key means following the order in which the form fields were created in the
design process.
Acrobat form
If the full version of Adobe Acrobat is installed on the computer being used for com-
pletion of the questionnaire, it is recommended that the Acrobat form is used. This
Figure I  Types of form field in the annual reports questionnaire, part II
 
  
 
 
 
 
     
 
 
 
 
 Numerical fields 
(Acrobat form) 
Multiple-line field 
(Word form) 
Single-line field 
(Word form) 
Boxes Text fields
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allows the user to print and save the form, as well as to interrupt and resume work
during completion of the form without loss of data. The Acrobat form should not
be used, however, if only the freely available Acrobat Reader is installed on the com-
puter, as Reader does not allow the user to save the completed form or resume work
on completion of the form after a break. The Acrobat form has the form fields and
built-in features described below.
Boxes
A small square box is provided below or next to a possible answer. By left-clicking
the mouse while the cursor is inside the box, a cross can be inserted. A second left
click of the mouse will delete the cross. When answer categories are mutually exclu-
sive, only one of the corresponding boxes can be marked.
Text fields
The amount of text that can be entered in text fields is limited by the size of the
form field and text should therefore be entered as concisely as possible. However,
if more space is required, a reference number may be entered in the text field con-
cerned and information or a description added under that reference number in the
section entitled “Additional information” on pages 22 and 23, as indicated in the
example given in figure II.
Numerical fields
When the answer to a question has to be a number, the field box will accept only
digits, or dots ( . ) as decimal separators, if applicable. Decimals will show on the
computer screen and in print with one decimal place, but all decimal places entered
will be retained in the electronic copy of the form. When the answer should logi-
 
 
 
 
 
 
 
 
 
 
  
          
  (3)  Psychedelic mushrooms
Figure II  Using reference numbers to provide additional information in the section entitled
“Additional information"
Label the detailed specification
with the same reference number
Insert a reference number when
the text field is too short
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cally be an integer such as a year or order of ranking, a decimal separator cannot
be entered.
Percentages should be entered in figures. The percentage symbol (%) should not be
added. If the original data are in the form of fractions, they should be converted to
percentages before being entered. For example, if 0.5 in the original data actually
means 50 per cent, 50 should be entered on the form. This will be displayed on the
form as 50.0; if 0.5 is entered, this will be interpreted as 0.5 per cent. 
When figures are equal to the value zero, 0 or 0.0 should be entered in form fields
rather than leaving them blank, otherwise the answer will be interpreted as miss-
ing, as it will for any other field left blank (see chapter III, above, on technical
aspects of completion). 
Word form
If it is desired to complete the questionnaire in Word document format, Microsoft
Word must be pre-installed on the computer. The questionnaire appears the same
in both Word and Adobe formats and either format will allow it to be easily saved
and printed, but the Word format questionnaire differs in that it has no dedicated
numerical fields in which only numbers can be entered.
Boxes
As in the case of the Acrobat format questionnaire, boxes in the Word format ques-
tionnaire are small and square and positioned below or next to a possible answer.
Left-clicking the mouse with the cursor inside a box will result in the box being
marked with a cross. Left-clicking again deletes the cross. Officials should be aware,
however, that the Word format questionnaire has no automatic mechanism that pre-
vents multiple answers being entered when categories are mutually exclusive. Care
should therefore be taken to ensure that in such cases only one of the appropriate
boxes is marked.
Text fields
The Word format questionnaire has no predefined numerical fields, so both text and
numbers can be entered in all fields. It should be noted that the TAB key cannot
be used within a text field as this key will move the cursor to the following field.
There is a difference between one-line and multi-line fields.
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Single-line text fields
If the size of a text field corresponds to only one line of text, the amount of text
that can be displayed on the screen or the printed copy will be limited to the size
of the field. More text may be entered than fits in the text box and the “invisible”
text will be stored on the questionnaire form, but the receiver of the questionnaire
will not know that the form field contains hidden text. It is recommended that text
in single-line fields be kept as concise as possible and that abbreviations be used if
necessary. If it is desired to add more information than fits in the field, separate
documents may be attached to the completed ARQ form. 
Multiple-line fields
If the size of a text field corresponds to more than one line, text that exceeds the
size of the field will cause the field to expand vertically, in extreme cases until the
text box touches the edges of the page. However, expanding the text box can cause
other questions and form fields in the document to be hidden and this limits the
practical use of the automatic expansion of the text fields (see figure III).
 
Figure III  Effect of automatic expansion of a text box when lengthy text is entered 
in a multiple-line text field (Word version of the ARQ) 
Lenghthy text expand field boxes
and covers other elements on the
Word form

Detailed notes on completion
of the annual reports 
questionnaire, part II
Chapter IV
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On the following pages, detailed notes on completion of the annual
reports questionnaire, part II, are given in the form of call-outs on
example pages of the ARQ.
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Prevalence of drug abuse 
among the general population SUMMARY EXPERT OPINIONS
Cannabis type  
Marijuana (herbal)   
Hashish (resin)
Opioids 
Heroin 
Opium
Cocaine type 
Powder (Salt) 
Crack 
Amphetamine type 
Amphetamine
Methamphetamine
‘Ecstasy’ type 
Sedatives & Tranquillisers* 
Barbiturates
Benzodiazepines
Hallucinogens 
LSD
Solvents & inhalants
Other drugs 
Ranking of drugs: 
Start in Q2 with 1 for the most
prevalent class of drugs, 2 for the
second most prevalent class, etc. 
If necessary, you can assign
equal rank numbers to more than
one class of drug. 
Continue with ranking individual
drug types in Q3 in order of
prevalence within each drug
class separately.
Q1
Have the
drugs
below
been used
in your
country in
the past
year? 
NO               YES
Q2
How are main
drug classes
ranked in
order of
prevalence?
Put in numerical
order
Class of drugs    
Type of drugs
Q3
Within each
drug class
separately,
how are drug
types ranked 
in order of
prevalence?
Put in numerical
order
Other
Other
Other
Complete Q2 and Q3
only when there has
been use of the drug
in the past year 
(Q1 = YES)
E/NR/2001/2
Figure IV  Prevalence of drug abuse among the general population: questions Q1-Q3 
Prevalence of drug abuse among the general population
Questions Q2 and Q3 should be completed
only when there has been use of the drug
in the past year (Q1 = YES).
YES should be marked if any
of the drugs listed have been
used. Any source may be
taken as evidence, including
anecdotal reports and unique
cases. 
NO should only be marked if
it is certain that a listed drug
has not been used at all.
If the names of
individual types of
drug are entered
in the first col-
umn, in question
Q2 they should
be ranked as for
classes of drug.
Non-prescribed/
non-therapeutic
use only.
TYPES OF DRUG within
each class of drug
should be ranked in this
column, starting with 1
for the most prevalen
typ  in each class, 2 for
the second most preva-
lent type, etc. Types of
drug with equal preva-
lence may be assigned
equal rankings.
CLASSES OF DRUG
should be ranked in this
column, starting with 1
for the most prevalent
class of drug, 2 for the
second most prevalent
class, etc. CLASSES OF
DRUG with equal preva-
lence may be assigned
equal rankings.
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Q5
What has been  the trend over the
past year in prevalence of each
drug type?
Q4
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
What has been the trend over the
past year in prevalence of each
drug class?
Cannabis type  
Marijuana (herbal)   
Hashish (resin)
Opioids 
Heroin 
Opium
Cocaine type 
Powder (Salt) 
Crack 
Amphetamine type 
Amphetamine
Methamphetamine
‘Ecstasy’ type 
Sedatives & Tranquillisers* 
Barbiturates
Benzodiazepines
Hallucinogens 
LSD
Solvents & inhalants
Other drugs 
Class of drugs    
Type of drugs
Other
Other
Other
Complete Q4 and Q5
only when there has
been use of the drug
in the past year 
(Q1 = YES)
Prevalence of drug abuse 
among the general population SUMMARY EXPERT OPINIONS
E/NR/2001/2
Figure V  Prevalence of drug abuse among the general population: questions Q4 and Q5
Questions Q4 and Q5 should be completed
only if there has been use of the drug in
the past year (Q1 = YES).
TREND should be interpreted
here as “change in the past
year compared to the previ-
ous year”.
Non-prescribed/
non-therapeutic
use only.
If the names of
individual types
of drug are
entered in the
first column, in
question Q2 the
perceived trend
in prevalence
over the past
year should be
indicated as for
classes of drug
The trend scale points refer to
the perception in the country,
not to any specific magnitude of
change. 
The scale point that corresponds
to the perceived change in the
country should be marked.
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Figure VI  Prevalence of drug abuse among the general population: questions Q6 and Q7 
Q6
Do you have an estimate of drug
prevalence among the general
population?
Tick ONLY ONE
Q7
For which year does the estimate apply?
Which part of the country or the population is covered by
the estimate?
Year of the national estimate
Year of the partial estimate
Part of the country or sub-population for which the estimate applies
No Proceed to Q10
Yes
an estimate for the country 
as a whole
Yes
an estimate for a part of the country
or a sub-population
Estimated size of the
reference population for
which the estimate applies
Prevalence of drug abuse 
among the general population QUANTITATIVE ESTIMATES
E/NR/2001/2
Only ONE of
the three boxes
should be
ticked for 
question Q6.
When a partial estimate is given
under question Q6, the area or
population coverage and the
(approximate) size of the reference
population should be specified.
T e ye r that applies to the estimate
may differ from the reporting year of
the ARQ or the year in which the
estimate was published.
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Figure VII  Prevalence of drug abuse among the general population: questions Q8 and Q9 
All ﬁgures should be rates
per 100 of population. 
You do not need to add %
after your ﬁgures.
Provide decimal ﬁgures. 
If an estimate results in 
a zero prevalence rate
please note as 0.
Please complete
questions Q8 – Q9 for
the estimate speciﬁed
in Q7 above
If you have an estimate of
the NUMBERS of users,
please convert these into
rates per 100 of the
reference population.
If you do not have ﬁgures
for the preferred age
range, you should specify
the age ranges that apply
to your estimates. 
If you do not have 
ﬁgures for the preferred
prevalence measure for
the reporting year, you
should specify the
prevalence measure
used for your estimate.
Cannabis type  
Opioids 
Heroin 
Opium
Cocaine type 
Powder (Salt) 
Crack  
Amphetamine type 
Amphetamine
Methamphetamine
‘Ecstasy’ type 
Sedatives & Tranquillisers* 
Barbiturates
Benzodiazepines
Hallucinogens 
LSD
Solvents & inhalants
Other drugs
Other
Other
Other
Preferred prevalence 
measure
Prevalence measure used
Preferred age range
Age range used
15-64 years
Q9
All % Females %
What is the estimated 
prevalence rate per 100
among the general
population in the
REPORTING YEAR?
Specify separately  for
the female population
All % Females %
15-64 years
Last 12 months
Q8
What is the estimated
LIFETIME prevalence
rate per 100 among the
general population?
Specify separately  for
the female population
Prevalence of drug abuse 
among the general population QUANTITATIVE ESTIMATES
E/NR/2001/2
LIFETIME
PREVALENCE
applies only to
estimates based
on survey data.
Preferred
prevalence
measure and
preferred age
range apply to
estimates
based on 
survey data.
Prevalence rates
should be stated in
rates per 100 of the
reference population
(percentages).
Non-prescribed/
non-therapeutic
use only.
Questions Q8 and Q9 should be completed
for the national or partial estimate specified
in question Q7.
If estimates are based
on survey data and the
prevalence measure
used was not “last 12
month ", the prevalence
measur  used should be
specified.
If stimat s are based
on survey data and the
age ranges that apply to
the estimates are not
“15-64 years", the age
ranges that apply to the
estimate should be 
specifi d.
Box should be moved to top of
table and point to the first two
answer boxes in columns Q8
and Q9]] When figures are equal
to the value zero, 0 or 0.0
should be entered, as leaving
cells blank will be interpreted as
“no estimate available”.
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Figure VIII  Prevalence of drug abuse among the school (youth) population: 
questions Q10 and Q11 
Prevalence of drug abuse 
among the school (youth) population QUANTITATIVE ESTIMATES
Q10
Do you have an estimate of drug 
prevalence among the 
school (youth) population?
Tick ONLY ONE
Q11
For which year does the estimate apply?
Which Part of the country or sub-population is covered by the
estimate?
Year of the national estimate
Year of the partial estimate
Part of the country or sub-population for which
the estimate applies
No Proceed to Q15
Yes
an estimate for the country 
as a whole
Yes
an estimate for a part of the country
or a sub-population
Estimated size of the
reference population for
which the estimate applies
E/NR/2001/2
Prevalence of drug abuse among the school (youth) population
Only ONE of the
three boxes
should be ticked
for question Q10.
When a partial estimate is given
under question Q10, the area or
population coverage and the
(approximate) size of the reference
population should be specified.
The year that applies to the
estimate may differ from the
reporting year of the ARQ or
the year in which the estimate
was published.
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Figure IX  Prevalence of drug abuse among the school (youth) population: questions Q12-Q14
Please complete
questions Q12 – Q14
for the estimate
speciﬁed in Q10
Q14
All % Females %
What is the estimated 
prevalence rate per 100
among the school
(youth) population in
the REPORTING YEAR?
Specify separately  for
the female population
All % Females %
Last 12 months
Q13
What is the estimated
LIFETIME prevalence
rate per 100 among 
the school (youth)
population?
Specify separately  for
the female population
15-16 years
Q12
All % Females %
What is the estimated 
prevalence rate per
100 among YOUNG
ADOLESCENTS
population in the
REPORTING YEAR?
Specify separately  for
the female population
 
Last 12 months
Prevalence of drug abuse 
among the school (youth) population QUANTITATIVE ESTIMATES
All ﬁgures should 
be rates per 100 
of population. 
You do not need 
to add % after
your ﬁgures.
Provide decimal
ﬁgures. If an
estimate results
in a zero
prevalence rate
please note 
as 0.
If you have an
estimate of the
NUMBERS of
users, please
convert these
into rates per 100
of the reference
population.
You should
always specify
the age ranges
used for the
estimates.
If you do not have
ﬁgures for the
preferred age
range of young
adolescents, you
should specify
the age range
that applies to
your estimates. 
If you do not 
have ﬁgures for
the preferred
prevalence
measure for the
reporting year,
you should
specify the
prevalence
measure used for
your estimate.
Cannabis type  
Opioids 
Heroin 
Opium
Cocaine type 
Powder (Salt) 
Crack  
Amphetamine type 
Amphetamine
Methamphetamine
‘Ecstasy’ type 
Sedatives & Tranquillisers* 
Barbiturates
Benzodiazepines
Hallucinogens 
LSD
Solvents & inhalants
Other drugs
Other
Other
Other
Preferred prevalence 
measure
Prevalence measure used
Preferred age range
Age range used
E/NR/2001/2
If estimates are based
on survey data and the
age range that applies to
the estimates is not 
"15-16 years", the AGE
RANGE that applies to
the estimates should be
indicated.
Prevalence rates should be
stated in rates per 100 of
the reference population
(percentages).
Box should be moved to
top of table and indicate
columns Q12-Q14. When
figures are equal to the
value zero, 0 or 0.0 should
be entered, as leaving cells
blank will be interpreted as
“no estimate available”.
Questions Q12-Q14 should be 
completed for the national or partial 
estimate specified in question Q10.
If estimates are based on
survey data and the 
prevalence measure used
was not “last 12 months", the
PREVALENCE MEASURE
used should be specified.
In questions Q13 and Q14
the AGE RANGE that
applies to the estimate
should be specified, even
if only approximate.
Preferred prevalence meas-
ure and preferred age range
apply to estimates based on 
survey data.
LIFETIME PREVALENCE
applies only to estimates
based on survey data.
Non-prescribed/
non-therapeutic 
use only.
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Figure X  Injecting drug abuse: questions Q15-Q18 
If there has been no
practice of injecting
(Q15, Any drugs = NO),
proceed to Q23.
Any drugs (type unspeciﬁed)
Heroin 
Other opioids  
Cocaine type  
Amphetamine  
Methamphetamine  
‘Ecstasy’ type
Other drugs
Q15
Has there 
been practice
of injecting
among drug
users in the
past year?
NO               YES
Q17
Has there been practice of sharing
needles or syringes among drug
injectors in the past year?
No Proceed to Q19
Q18
What has been the trend over
the past year in sharing
needles or syringes among
drug injectors?
Yes
Q16
What has been the
trend in injecting over
the past year?
With ‘sharing’
needles or syringes
we mean ‘using a
needle or syringe
that has been used
previously by
someone else’.
Injecting drug abuse SUMMARY EXPERT OPINIONS
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
E/NR/2001/2
Injecting drug abuse
Questions Q16-Q18 should only be completed
if there has been injecting drug use in the past
year (Q15 = YES).
If information about
injecting use of
individual drugs is
not available, an
estimate should be
provided for ANY
DRUGS.
"Sharing needles or
syringes” means 
"using a needle or
syringe that has b en
used previously by
someone else”.
TREND should be interpreted
here as “change in the past year
compared to the previous year”.
The trend scale points refer to
the perception in the country,
not to any specific magnitude
of change. The scale point that
corresponds to the perceived
change in the country should
be marked.
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Figure XI  Injecting drug abuse: questions Q19-Q22
Please complete
question Q21 for the
estimate speciﬁed in
Q20
Q22
What is the estimated
PERCENTAGE of active drug
injectors who report to have
shared needles or syringes
the last time they injected
drugs?
Q19
Do you have an estimate of the
percentage or number of drug injectors
among all drug users?
Tick ONLY ONE
Q20
For which year does the estimate apply?
Which part of the country or subgroup of drug users 
is covered by the estimate?
Year of the national estimate
Year of the partial estimate
Part of the country or subgroup of drug users for which the
estimate applies
Estimated size of the
reference population
for which the
estimate applies
No Proceed to Q23
Yes 
an estimate for the country as a whole
Yes
an estimate for a part of the country or
a subgroup of drug users
If there has been no practice
of sharing (Q17 = NO),
proceed to Q23
Injecting drug abuse QUANTITATIVE ESTIMATES
Any drugs (type unspeciﬁed)
Heroin 
Other opioids  
Cocaine type  
Amphetamine  
Methamphetamine  
‘Ecstasy’ type
Other drugs
Q21a
What is the
estimated
PERCENTAGE of
drug injectors
among all 
drug users?
Q21b
What is the
estimated
NUMBER 
of drug
injectors?
E/NR/2001/2
Only ONE of the
three boxes should
be ticked for 
question Q19.
When a partial 
estimate is given
under question
Q19, the area or
population 
coverage and the
(approximate) size
of the reference
population should
be specified. 
The year that applies to the esti-
mate may differ from the reporting
year of the ARQ or the year in
which the estimate was published.
Questions Q21a-Q22
should be completed for
the national or partial
estimate specified in
question Q25.
"Sharing needles or syringes”
means “using a needle or syringe
that has been used previously by
someone else”.
When figures are equal to the value
zero, 0 or 0.0 should be entered, as
leaving cells blank will be interpreted
as “no estimate available”.
Presenting an estimated 
percentage of injectors among
all drug users implies that an
estimate of the total number of
active drug users is also 
available (see question Q9).
If information about injecting
use of individual drugs is not
available, an estimate should
be provided for ANY DRUGS.
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Figure XII  Severe drug abuse: questions Q23-Q28 
Severe drug abuse SUMMARY EXPERT OPINIONS
Q23
Does your country make a distinction
between drug users in general and drug
users who are considered particularly
problematic, chronic or in need of help?
Q24
What has been the trend over 
the past year in “severe /
problematic” drug use?
No Proceed to Q29
Yes
Please complete
questions Q27 – Q28
for the estimate
speciﬁed in Q26
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
Q25
Do you have an estimate of drug users,
who are considered particularly
problematic, chronic users or in need 
of help?
Tick ONLY ONE
Q26
For which year does the estimate apply?
Which part of the country or which subgroup of drug users
is covered by the estimate?
Year of the national estimate
Year of the partial estimate
Part of the country or subgroup of drug users for which the
estimate applies
Estimated size of 
the reference
population for which
the estimate applies
No Proceed to Q29
Yes 
an estimate for the country as a whole
Yes
an estimate for a part of the country or
a subgroup of drug users
Q28
Which deﬁnition of “severe / problematic users”
applies to the estimated number of Q27 and how is
the estimate calculated?
Q27
What is the estimated number of 
“severe / problematic” drug users?
Severe drug abuse QUANTITATIVE ESTIMATESSevere drug abuse QUANTITATIVE ESTIMATES
E/NR/2001/2
Severe drug abuse
TREND should be 
interpreted here as
“change in the past 
year compared to the
previous year”.
The trend scale points refer to the perception in the
country, not to any specific magnitude of change. 
The scale point that corresponds to the perceived
change in the country should be marked.
Only ONE of the
three boxes
should be ticked
for question Q25
When a partial estimate is given
under question Q25, the area or
population coverage and the
(approximate) size of the reference
population should be specified.
If no strict definition of “severe/problematic
users” can be supplied, at least the
method of estimation should be specified.
The data sources used in the estimation
should also be specified, if applicable.
Questions Q27 and Q28
should be nswered for
the national or partial
estimate specified in
question Q25.
The year that applies to the esti-
mate may differ from the reporting
year of the ARQ or the year in
which the estimate was published.
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New developments in prevalence and patterns of drug abuse
Figure XIII  New developments in prevalence and patterns of drug abuse: questions Q29-Q32
Q29
Have new drugs or new patterns of drug
use been reported in the past year?
Q30
Which new drugs or new patterns of use
have been reported?
New developments in prevalence and 
patterns of drug abuse SUMMARY EXPERT OPINIONS
No Proceed to Q31
Yes
Q32
Which new groups of drug users have been
reported and in relation to which types of drugs?
No Proceed to Q33
Yes
Q31
Have new groups of drug users been
reported in the past year?
E/NR/2001/2
Drugs or patterns of drug use are
considered “new” if they were
observed in the past year but not
in the previous year. NEW DRUGS
AND PATTERNS OF DRUG USE
may include drugs and patterns of
drug use that have recurred after
a year or more of absence. 
A concise but explicit description of new
drugs or patterns of drugs should be given.
A concise but explicit description of new
groups of drug users and the types of drug
being used by them should be given.
NEW GROUPS OF USERS means
any group of people defined by com-
mon social, demographic, ethnic, cul-
tural or other characteristics, including
people in certain parts of the country,
among whom, according to formal
reports or expert opinions, drug use
has been observed in the past year,
but not in the previous year.
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Figure XIV  New developments in prevalence and patterns of drug abuse: developments in 
prevalence and patterns of drug use not covered in the present questionnaire 
New developments in prevalence and 
patterns of drug abuse SUMMARY EXPERT OPINIONS
Please use the space below to document any other  developments in prevalence and patterns
of drug abuse  in your country over the past year. 
E/NR/2001/2
This space should be used to add comments on, explanations of 
and references to the expert opinions and quantitative estimates 
presented in the responses to questions Q1-Q32. It may also be used
to inform the United Nations Office on Drugs and Crime of other 
relevant developments in prevalence and patterns of drug use not 
covered in the present questionnaire.
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Figure XV  Drug-related morbidity: questions Q33-Q38 
Drug-related morbidity SUMMARY EXPERT OPINIONS
Q34
What has been the trend over 
the past year in prevalence of
infections among drug injectors?
Please complete
questions Q37 – Q38
for the estimate
speciﬁed in Q36
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
Q35
Do you have an estimate of drug
injectors having any of the infections
mentioned in the table above?
Tick ONLY ONE
Q36
For which year does the estimate apply?
Which part of the country or which subgroup of drug
injectors is covered by the estimate?
Year of the national estimate
Year of the partial estimate
Part of the country or subgroup of drug injectors for which
the estimate applies
Estimated size of the
reference population
for which the
estimate applies
No Proceed to Q39
Yes 
an estimate for the country as a whole
Yes
an estimate for a part of the country or
a subgroup of drug injectors
Q38
What is the estimated PERCENTAGE of
infected persons among drug injectors?
Q37
What is the estimated NUMBER of
infected drug injectors?
Drug-related morbidity QUANTITATIVE ESTIMATES
Q33
Have there been
reports about
prevalence of
infections among
drug injectors in 
the past year?
NO               YES
Hepatitis B  
Hepatitis C 
HIV
Hepatitis B  
Hepatitis C 
HIV
E/NR/2001/2
Drug-related morbidity
Information is only required on
the three infections listed.
Information on other infections
or diseases may be given in
the section entitled “Additional
information” at the end of the
questionnaire.
TREND should be
interpreted here as
“change in the past
year compared to 
the previous year”.
The trend scale points refer to
the perception in the country,
not to any specific magnitude
of change. The scale point that
corresponds to the perceived
change in the country should
be marked.
Presenting an 
estimated percent-
age of infected drug
injectors among drug
injectors implies that
an estimate of the
total number of drug
injectors is also
available (see 
question Q21b).
The year that applies to the estimate
may differ from the reporting year of
the ARQ or the year in which the 
estimate was published.
Only ONE of the
three boxes
should be ticked
for question Q35.
When a partial estimate is given
under question Q35, the area or
population coverage and the
(approximate) size of the reference
population should be specified.
When figures are equal to the value zero, 0 or
0.0 should be entered, as leaving cells blank will
be interpreted as “no estimate available”.
Questions Q37 and Q38
should be answered for
the national or partial
estimate specified in
question Q36.
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Figure XVI  Drug-related mortality: questions Q39-Q41 
Q40
How are drugs
ranked in order
of the primary
cause in drug-
related deaths?
Put in numerical order
Ranking of drugs as primary cause in
drug-related deaths:
Start with 1 for the drug most frequently
the primary cause in drug-related deaths,
2 for the second most frequent primary
cause, etc. If necessary, you may assign
equal rank numbers to more than one
drug.
Any drugs (type unspeciﬁed)
Heroin 
Other opioids  
Cocaine type  
Amphetamine  
Methamphetamine  
‘Ecstasy’ type
Other drugs
Q39
Have there been
reports about
drug-related
deaths in the
past year?
NO               YES
Q41
What has been the trend over
the past year in drug-related
deaths?
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
Drug-related mortality SUMMARY EXPERT OPINIONS
E/NR/2001/2
Drug-related mortality
If information about
deaths related to the use
of individual drugs is not
available, an estimate
should be provided for
ANY DRUGS.
TREND should be
interpreted here as
“change in the past
year compared to
the previous year”.
The trend scale points refer to
the perception in the country,
not to any specific magnitude of
change. The scale point that
corresponds to the perceived
change in the country should
be marked.
In the column under
question Q40 drugs
should be ranked in
order of the primary
cause of drug-related
deaths, starting with 1
for the drug most often
reported as the primary
cause of drug-related
deaths, 2 for the drug
second ost reported,
etc. When different
drugs are the cause of
equal numb rs of
deaths, they may be
assigned equal rankings.
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Figure XVII  Drug-related mortality: questions Q42-Q47 
Drug-related mortality QUANTITATIVE ESTIMATES
Q42
Do you have an estimate of the number
of drug-related deaths?
Tick ONLY ONE
Q43
For which year does the estimate apply?
Which part of the country or sub-population is
covered by the estimate?
Year of the national estimate
Year of the partial estimate
Part of the country or sub-population for which 
the estimate applies
Estimated size of the
reference population
for which the
estimate applies
No Proceed to Q48
Yes 
an estimate for the country as a whole
Yes
an estimate for a part of the country or
a sub-population
Please complete
questions Q44 – Q47
for the estimate
speciﬁed in Q43
Any drugs (type unspeciﬁed)
Heroin 
Other opioids  
Cocaine type  
Amphetamine  
Methamphetamine  
‘Ecstasy’ type
Other drugs
Q44
What is the
estimated
TOTAL
number of
drug-related
deaths?
Q45
What is the
estimated
number of
FATAL DRUG
OVERDOSES
ONLY?
Q46
What is the
estimated
number of
drug-related
AIDS
DEATHS?
Q47
What is the
estimated number
of drug-related
OTHER DEATHS
(excluding fatal
drug overdoses
and AIDS deaths)?
E/NR/2001/2
Only ONE of the three
boxes should be ticked
for question Q42. 
The year that applies to the estimate
may differ from the reporting year of
the ARQ or the year in which the
estimate was published.
When a partial estimate is given
under question Q42, the area or
population coverage and the
(approximate) size of the reference
population should be specified.
When figures are equal to the
value zero, 0 or 0.0 should be
entered, as leaving cells blank
will be interpreted as “no esti-
mate available”.
Questions Q44-Q47 should be
answered for the national or partial
estimate specified in question Q42.
If the information required to answer
questions Q44-Q47 on drug-related
deaths caused by individual drugs is
not available, an estimate should be
provided for ANY DRUGS.
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Figure XVIII  Drug treatment: questions Q48-Q52 
Q49
How are drugs
ranked in order
of the primary
cause of
receiving
treatment?
Put in numerical order
Ranking of drugs as
primary cause of
treatment:
Start with 1 for the
drug most frequently
the primary cause of
treatment, 2 for the
second most
frequent primary
cause, etc. If
necessary, you may
assign equal rank
numbers to more
than one drug.
Any drugs (type unspeciﬁed)
Cannabis type
Heroin 
Other opioids  
Cocaine type  
Amphetamine  
Methamphetamine  
‘Ecstasy’ type
Other drugs
Q48
Have people
received
treatment for
drug problems
in the past
year?
NO               YES
Q50
What has been the trend over
the past year in the numbers of
people receiving treatment?
Large 
increase
Some
increase
No great
change
Some
decrease
Large 
decrease
Q51
Do you have an estimate of the number
of people receiving treatment for drug
problems?
Tick ONLY ONE
Q52
For which year does the estimate apply?
Which part of the country or selection of treatment
facilities is covered by the estimate?
Year of the national estimate
Year of the partial estimate
No Proceed to Q59
Yes 
an estimate for the country as a whole
Yes
an estimate for a part of the country or
a selection of treatment facilities
Drug treatment SUMMARY EXPERT OPINIONS
Part of the country for which the estimate applies
Types of treatment facilities included and/or excluded 
in the estimate
Drug treatment QUANTITATIVE ESTIMATES
E/NR/2001/2
Drug treatment
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If the information
required to answer
questions Q48-Q50 on
treatment given for
problems caused by
individual drugs is not
available, an estimate
should be provided for
ANY DRUGS.
In the column under question Q49
drugs should be ranked in order of the
primary cause of receiving treatment,
starting with 1 for the drug most often
reported as the primary cause of
receiving treatment, 2 for the drug
second most reported, etc. When 
different drugs are the cause of equal
numbers of people receiving treatment,
they may be assigned equal rankings.
The trend scale points refer to
the perception in the country,
not to any specific magnitude of
change. The scale point that
corresponds to the perceived
change in the country should
be marked.
TREND should be
interpreted here as
“change in the past
year compared to
the previous year”.
The year that applies to the estimate
may differ from the reporting year of
the ARQ or the year in which the
estimate was published.
Only ONE of the three
boxes should be ticked
for question Q51.
When a partial estimate is given under
question Q51, the area coverage should be
specified. If treatment in the country is
restricted to specific groups of the popula-
tion, for example, citizens only, the exclud-
ed groups should also be specified.
A concise but explicit description should
be given of the types of general and
specialized treatment facilities included
in and/or excluded from the estimate.
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Figure XIX  Drug treatment: questions Q53-Q58 
Please complete
questions Q53 – Q58
for the estimate
speciﬁed in Q52
Any drugs (type unspeciﬁed)
Cannabis type
Heroin 
Other opioids  
Cocaine type  
Amphetamine  
Methamphetamine  
‘Ecstasy’ type
Other drugs
Q53
What is the
estimated
NUMBER 
of people
receiving
treatment 
for drug
problems?
Q54
What is the
estimated
PERCENTAGE
of people
receiving
treatment for
the FIRST 
TIME EVER
among people
in treatment?
Q55
What is the
estimated
PERCENTAGE
of FEMALES
among people
in treatment
Q56
What is the
estimated
MEAN AGE 
of people in
treatment?
Q57
What is the
estimated
PERCENTAGE
of DRUG
INJECTORS
among people
in treatment?
Drug treatment QUANTITATIVE ESTIMATES
If estimates for ‘all drugs’ in Q53-Q57 above include also treatment for alcohol problems,
please tick here 
Q58
All people receiving treatment
during the year 
People STARTING treatment
during the year
People in treatment at CENSUS
DATE in the year
People discharged from
treatment during the year
Other
Tick as
Appropriate   
Tick as
Appropriate   
Tick as
Appropriate   
Tick as
Appropriate   
Tick as
Appropriate   
Which deﬁnition of ‘people treated for drug problems’
applies to the ﬁgures in the columns of Q53 –Q57  above? 
Q53 Q54 Q55 Q56 Q57
E/NR/2001/2
Questions Q53-Q57 should be answered for the
national or partial estimate specified in question Q51.
When figures are equal to the value zero, 0 or 0.0
should be entered, as leaving cells blank will be
interpreted as “no estimate available”.
Only one answer should be marked in each column.
The definition 
applicable to each 
column of estimates 
Q53-Q57 should be
marked.
A concise but
explicit alterna-
tive definition of
people treated
for drug prob-
lems should be
given.
If estimates relating to “any drugs”
were provided under questions
Q53-Q57 and those estimates
included treatment for alcohol 
problems, this should be indicated
by marking the box
If the information required to
answer questions Q53-Q57
about the numbers of people
receiving treatment for drug
problems caused by individual
drugs is not available, an 
estimate should be provided
for ANY DRUGS.
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Figure XX  Data collection capacity: questions Q59-Q61 
Data collection capacity
Q60
Poor Moderate Good
How would you qualify
the present suitability 
of these instruments 
for making national
estimates about the 
drug situation?
Q59
Has your country
capacity with
regard to data
collection
instruments
speciﬁed below?
Q61
If applicable, what are the main obstacles for implementation or improvement of data
collection instruments suitable for making national estimates about the drug situation?
Registers
Specialised treatment register 
Registers on drug-related morbidity
Registers on drug-related mortality
Survey instruments
Prevalence surveys among  the general
population
Prevalence surveys among school
populations
Surveys among drug users
Qualitative research instruments
Rapid Situation Assessment
Other
NO               YES
E/NR/2001/2
Data collection capacity
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CAPACITY should be inter-
preted as “having established
or being able to establish 
registers or conducting or
being able to conduct surveys
or assessments”.
A concise but explicit
description should be
given of the types of
data collection 
instrument available 
in the country.
A concise but explicit description
of the main obstacles to the
establishment or improvement of
data collection instruments
should be given.
Question Q60 should
only be completed if
data collection capacity
exists in the country
(Q59 = YES).
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Figure XXI  Reports 
Please list below relevant national reports or major studies about the extent,
patterns or trends in drug abuse in your country, published in the past year. 
Specify author, title and year of publication. Attach copies of documents and
reports if possible. 
Reports
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
E/NR/2001/2
Reports and additional information
37
At a minimum, references should be 
provided to the publications containing
details of the quantitative estimates 
supplied in the preceding sections of the
ARQ. If possible, electronic or hard
copies of the reports listed in the 
completed questionnaire should be
attached, in particular when such reports
have not been published. If a report is
available on the Internet, the URL
address should also be supplied.
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Figure XXII  Additional information
Please use the space below to add notes of clariﬁcation to any of the
information contained in this questionnaire or to document any issue that you
wish to draw to the attention of UNDCP.
Additional information
E/NR/2001/2
The following information should be given here:
(a) Answers that could not fit in the form fields
provided;
(b) Relevant information not consistent with 
figures reported in the indicator tables;
(c) Any further information about the drug 
situation in the country not covered in the
questionnaire.
Glossary of terms
Chapter V
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In the present chapter, a non-exhaustive list of terms used in the
annual reports questionnaire, together with their definition or descrip-
tion, is presented. Although the terminology used in the question-
naire is commonly used in the field of drug epidemiology and the
meaning of many terms may be considered self-evident, some termi-
nology may require explanation, in particular when terms are used in
the questionnaire to convey a particular or restricted meaning. The
present list of terms does not include descriptions of individual drugs.
Further information on the terms used in drug epidemiology can be
found in Demand Reduction: A Glossary of Terms, published by the
United Nations Office on Drugs and Crime of the Secretariat [6], and
Lexicon of Alcohol and Drug Terms [7],  published by the World
Health Organization.
Drug treatment
The process of intervention directed towards individual active drug
users offered by providers of health, social or community services,
aiming at ending or reducing the use of drugs or the negative conse-
quences of drug use. Drug treatment comprises treatment for drug
addiction or drug dependency, as well as harm or risk reduction inter-
ventions that do not primarily aim to address dependency, and social
and community support services targeted at drug users. In principle,
any services offered by a health, social or community service that
relate to their clients’ drug use or offers of care and support made
because clients are known to be drug users can be labelled drug treat-
ments. In practice, the concept of drug treatment and the modalities
of drug treatment vary among countries. For the purposes of com-
pletion of the annual reports questionnaire, a country should regard
as drug treatment all service provision that is perceived as drug treat-
ment by a majority of that country’s experts on drug abuse.
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Drug-related AIDS deaths
Deaths among drug users where AIDS has been assessed as the direct underlying
cause of death and drug injecting has been identified as the mode of transmission
of HIV. In principle, the concept should be comparable across countries, although
some countries may declare all AIDS deaths among injecting drug users drug-related
AIDS deaths, even if the transmission mode of HIV has not been identified. 
Drug-related morbidity
The extent of diseases related to or associated with the use of illicit drugs. This
includes diseases directly or indirectly caused by the intake of illicit drugs, as well
as diseases of which the use of illicit drugs is a contributory cause. As there is no
exhaustive list of such diseases, in epidemiology the concept of drug-related mor-
bidity is usually confined to the extent of a specific number of diseases or infections
among specific groups of drug users. In the ARQ, drug-related morbidity refers to
infections of hepatitis B, hepatitis C and HIV among drug users who inject or have
injected illicit drugs. It is usually reported as (cumulative) incidence of detected cases
of these infections whereby drug injecting has been identified as the mode of trans-
mission. The ARQ, part II, asks for estimates of the total number of infected drug
injectors and the estimated percentage of infected injectors. 
Drug-related mortality
The extent of deaths related to or associated with the use of illicit drugs. This
includes deaths directly or indirectly caused by the intake of illicit drugs, but it may
also include deaths where the use of illicit drugs is a contributory cause, including
cases where drug use is involved in the circumstances of deaths (for example, vio-
lence and traffic accidents). Although there are international standards for the clas-
sification of deaths (for example, International Classification of Diseases and Related
Health Problems, Ninth Revision (ICD-9) [8] and International Statistical Classification
of Diseases and Related Health Problems, Tenth Revision (ICD-10), [9]  both pub-
lished by the World Health Organization, and International Classification of Diseases,
Ninth Revision: Clinical Modification (ICD-9-CM), [10] there is no consensus among
experts on which deaths should be classified as drug-related or on methods of record-
ing death cases. In the ARQ, therefore, countries should report overall drug-related
mortality according to their own definitions and practice. As these will vary from
country to country, reported figures will not be comparable across countries. In order
to improve comparability, the ARQ also asks for separate information, if available,
on fatal drug overdoses and AIDS deaths among drug users, for which the defini-
tions used are less ambiguous and for which the reported figures can be expected
to be more or less comparable across countries. 
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Fatal drug overdose
Case of death where an overdose or intoxication with illicit drugs has been assessed
as the direct underlying cause of death. These cases can be identified from general
mortality registers based on ICD-9 or ICD-10 or from special mortality registers if
they include drug overdose as a separate category. Although the actual practices of
examination and recording of deaths will vary from country to country, reported fig-
ures on fatal drug overdoses should, in principle, be comparable among countries. 
Illicit drug
Any drug listed in the schedules to the international drug control conventions whose
origin (that is, production, cultivation, sale or acquisition) was illicit or illegal. The
latter qualification, “illegal", would imply that controlled substances used for med-
ical or scientific purposes are not illicit. In the ARQ, however, this condition regard-
ing illicit origin, which, in the context of drug use, means “non-medical or
non-therapeutic use” is only specifically mentioned for sedatives and tranquillizers,
but it should be assumed that it also applies to other drugs. In the context of preva-
lence estimates, the ARQ also asks, according to common international practice, for
information on the use of solvents and inhalants as far as they are used as psy-
choactive drugs, although the substances themselves may not be included in the
international conventions. 
Injecting drug use/user
Taking drugs by means of injecting or the person doing so. These terms are often
abbreviated to IDU. In many cases, drugs are injected intravenously and, in the past,
injecting drug use has been referred to as intravenous drug use, but as injecting can
also be subcutaneous (under the skin) or intramuscular (into the muscle tissue),
injecting drug use is considered the more appropriate term.
In general, drug users will only be labelled “injecting drug users” if they have 
injected drugs at least once during the last 12 months. In the context of drug-related
morbidity and mortality, however, many countries may include anyone who has once
been recorded or notified as an injecting drug user, whether or not they have 
injected drugs in the previous 12 months.
New drug/pattern of use/user group
In the ARQ, the term “new” should apply to any drug, pattern of use or specific
group of users if this drug, pattern of use or user group has been observed in the
country in the reporting year, but not in the year prior to the reporting year. However,
the interpretation of the term “new” will depend on the perspective of each report-
ing country and countries should report accordingly.
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Patterns of drug use
In the ARQ, this refers to a rather broad concept that includes how drugs are used
(the modes or routes of administration, regularity, intensity and frequency), in which
environment or circumstances they are used (the site and setting of use), for which
reasons, and so forth. 
Prevalence of drugs
The extent of drug use among a reference population during a reference period. It
is expressed as a percentage of a specified reference population that has taken drugs
at least once during the reference period.
For the general population, the age group of 15-64 years is, according to interna-
tional consensus, the standard reference population. For the youth population, the
age group of 15-24 years is the common standard reference population.
The international standards for reference periods are lifetime (lifetime prevalence or
“ever use”), last 12 months (last 12 months’ prevalence or “recent use”) and last
30 days (last 30 days’ prevalence or “current use”). As the ARQ refers to a specif-
ic reporting year, the basic reference period is last year prevalence, but for the quan-
titative estimates the ARQ also asks for lifetime prevalence figures. With regard to
the youth population, the ARQ also asks for quantitative estimates among young
adolescents of 15-16 years of age, as this age group is the most common interna-
tional standard used in school surveys on drug prevalence. 
Severe drug abuse (problem drug use)
In the ARQ, this refers to drug use that, from the perspective of the reporting coun-
try, is considered particularly problematic or chronic or to drug users who need help
in stopping, reducing or controlling their drug use. The concept only applies when
countries differentiate between types or patterns of drug use. Even if countries do
differentiate, their definitions are likely to vary and the ARQ therefore requires the
definition that applies to be specified.
Sharing needles or syringes
Using a needle or syringe that has been used previously by someone else. The extent
of sharing is usually identified by asking active drug injectors if they shared a 
needle or syringe the last time they injected drugs or if they have shared needles or
syringes at least once in the previous 12 months. 
Classification of drugs
Chapter VI
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The list below provides an overview of the classification of drugs used
in the annual reports questionnaire. More detailed descriptions of
individual drugs may be found in the publication entitled Terminology
and Information on Drugs, published by the United Nations
International Drug Control Programme [4].
Class of drug Alternative Type of drug
aggregate
class of drug
Cannabis type Marijuana (herbal)
Hashish (resin)
Opioids Heroin Heroin
Other opioids Opium
Other
Cocaine type Powder (salt)
Crack
Other
Amphetamine type Other amphetamines Amphetamine
Methamphetamine
Ecstasy type Ecstasy type
Sedatives and tranquillizers Barbiturates
Benzodiazepines
Hallucinogens Lysergic acid diethylamide
(LSD)
Other 
Other drugs
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